Shots:

• AbCellera acquires TetraGenetics in an all-cash transaction that includes up front- milestones based on the achievement of technical milestones related to the development of therapeutics
• The acquisition will combine TetraGenetics’ capabilities with AbCellera’s technology to provides an optimized protein source for AbCellera’s Abs discovery across a range of therapeutic areas. The technology has the potential to unlock the discovery of Abs against validated and drug targets
• TetraGenetics offers a protein expression platform that generates recombinant human ion channels- GPCR- and other transmembrane proteins to support Ab discovery

  | Ref: AbCellera | Image: AbCellera